Predictive markers in breast and other cancers: A review

Clinical Chemistry

Volumn 51, Issue 3, 2005, Pages 494-503

  Duffy, Michael J ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIPODOPHYLLOTOXIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GLYCOPROTEIN P; GONADORELIN; HORMONE; METHOTREXATE; PLATINUM; PROGESTERONE RECEPTOR; RALTITREXED; TAMOXIFEN; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; VINCA ALKALOID;

APOPTOSIS; BREAST CANCER; CANCER MORTALITY; CHEMOTHERAPY; COLORECTAL CANCER; DNA MICROARRAY; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOLOGY; OVARY CANCER; PATIENT SELECTION; REVIEW; TESTIS CANCER; TUMOR REGRESSION;

ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 14544270950     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.046227     Document Type: Review

References (82)

1. Hortobaggi G. Treatment of breast cancer. N Engl J Med 1998;339:974-84.
2. Picart MJ, Bertelson K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized inter-group trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three years results. J Natl Cancer Inst 2000;92:699-708.
3. Changanti RSK, Houldsworth J. Genetic and biology of adult human male germ cell tumors. Cancer Res 2000;60:1475-82.
4. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997;80:1179-87.
5. Duffy MJ. Biochemical markers as prognostic indices in breast cancer. Clin Chem 1990;36:188-91.
6. Duffy MJ. The biochemistry of metastasis. Adv Clin Chem 1996;32:135-66.
7. Isaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol 2001;28:53-67.
8. Olefsky JM. Nuclear receptor minireview series. J Biol Chem 2001;276:36863-4.
9. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, et al. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr Relat Cancers 2003;10:193-202.
10. Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000;65:571-7.
11. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone A form is a cell and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993;7:1244-55.
12. Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP. The A and B form of human progesterone receptor operate through distinct signalling pathways within target cells. Mol Cell Biol 1994;14:8356-64.
13. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998;4:527-34.
14. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollner EP, eds. Estrogen receptors in human breast cancer. New York: Raven Press, 1975:1-8.
15. McGuire WL. Steroid hormone receptors in breast cancer treatment strategy. Rec Prog Hormone Res 1980;36:135-56.
16. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of randomized trials. Lancet 1998;351:1451-67.
17. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in 2 large breast cancer databases. J Clin Oncol 2003;21:1973-9.
18. Hopp TA, Weiss HL, Hilsenneck SG, Cui Y, Allred DC, Horwitz KB, et al. Breast cancer patients with progesterone receptor PR-A rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004;10:2751-60.
19. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MRJ, Hanby AM. Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol 2004;5:174-81.
20. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor β mRNA in tamoxifen resistant breast cancer patients. Cancer Res 1999;59:5421-4.
21. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, et al. Estrogen receptor β (ER-β) but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004;10:5769-76.
22. Bast RC, Ravdin P, Hayes DF, Bates B, Fritsche H, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
23. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL. Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche H, Scharwtz MK, Chan DW, eds. Tumor markers: physiology, pathobiology, technology and clinical applications. Washington: AACC Press, 2002:33-63.
24. Molina R, Duffy MJ, Aronsson AC, Lamerz R, Stieber P, van Dalen A. Tumor markers in breast cancer, EGTM recommendations. Anticancer Res 1999;19:2785-820.
25. Blamey RW. Guidelines on endocrine therapy of breast cancer, EUSOMA. Eur J Cancer 2002;38:615-34.
26. National Institute of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
27. Harvey JM, Clark GM, Allred C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
28. Olayioye MA, Neve RM, Lane HA, Hynes NE. The erbB signalling network: heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
29. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28(Suppl 3):13-9.
30. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer. Am J Clin Pathol 2004:121(Suppl 1):S33-49.
31. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanisation of an anti p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
32. Albanell J, Baselga J. Unravelling resistance to trastuzumab (herceptin): insulin-like growth factor-1 receptor, a new suspect. J Natl Cancer Inst 2001;93:1830-2.
33. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanised anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
34. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med 2001344:783-92.
35. Piccart MJ, Di Leo A, Hamilton A. HER2: a predictive factor ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:1755-61.
36. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56.
37. Hayes DF, Bast R, Desch CE, Fritsche H, Kemeny NE, Jessup JM, et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
38. Velculescu V, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858-68.
39. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
40. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
41. El-Deiry WS. The role of p53 in sensitivity and radiosensitivity. Oncogene 2003;22:7486-95.
42. Elledge R, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998;52:79-98.
43. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Cancer 2001;1:233-40.
44. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001;38:225-62.
45. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66.
46. Gottesman MM, Fozo T, Bates S. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
47. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-24.
48. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance [Review]. Eur J Cancer 1996;32A:979-84.
49. Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 2002;98:323-30.
50. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
51. Marie J-P, Zhou D-C, Gurbuxani O, Legrand O, Zittoun R. MDR1/ P-glycoprotein in haematological neoplasms. Eur J Cancer 1996;32A:1034-8.
52. Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp C, et al. MDR gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2000;18:2685-94.
53. Pinedo HM, Peters GJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
54. Longley DB, Harkin P, Johnston PG. 5-Fluorouracil: mechanism of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
55. van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999;5:643-54.
56. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorl R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002;1587:164-73.
57. Bertino JR, Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clin Cancer Res 2003;9:1235-9.
58. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-35.
59. Macgregor PF, Squire JA. Application of microarray to the analysis of gene expression in cancer. Clin Chem 2002;48:1170-7.
60. Winegarden N. Microarrays in cancer: moving from hype to clinical reality. Lancet 2003;362:1428.
61. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
62. Staunton JE, SlonimColler HA, Tamayo P, Angelo MJ, Park J, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
63. Chang JC, Wooten EC, Tsimeizon A, Hilsenbeck SG, Gutierrrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
64. Ayers M, Symmams WF, Stec J, Damokosh Al, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
65. Holleman A, Meyling MH, den Boer ML, Yang W, Veerman AJP, Kazemier KM, et al. Gene expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-42.
66. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, et al. Relation between resistance to Philadelphia-chromosome-positive acute lymphoblastic leukemia to the tyrosine kinase inhibitor STI571 and gene expression profile: a gene expression study. Lancet 2002;359:481-6.
67. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464-8.
68. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004;23:1-8.
69. Di Leo A, Isola J. Topoisomerase IIα as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 2003;4:179-86.
70. Harbeck N, Kates RE, Look MP Meijer-van Gelder ME, Klijn JG, Kruger A, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (N = 3424). Cancer Res 2002;62:4617-22.
71. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualised therapy in primary breast cancer is greatest when used in combination. J Clin Oncol 2002;20:1000-7.
72. Foekens J, Look MP, Peters HA van Putten WU, Portengen H, Klijn JGM. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995;87:751-6.
73. Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N, et al. Urokinase-type plasminogen activator (uPA) system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 2004;64:4563-8.
74. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR, Harris AL. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989;1:182-5.
75. Spyratos F, Andrieu C, Hacene K, Chambon P, Rio MC. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994;69:394-7.
76. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-vanGelder ME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-14.
77. Manders P, Sweep FCG, Tjan-Heijnen VC, Geurts-Moespot A, van Tienoven DT. Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. Clin Cancer Res 2003;9:6363-70.
78. Span PN, Lindberg RLP, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, et al. Tissue inhibitor of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol 2004;202:395-402.
79. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, et al. Y-box factor YB-1 predicts drug resistance and patient outcome independent of clinically relevant tumor biologic factors HER-2, UPA and PAI-1. Int J Cancer 2002;97:278-82.
80. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutation and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003;21:4342-9.
81. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004;350:2129-39.
82. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib. Science 2004;304:1497-500.